Continuity of Care
Credit: vm/Getty Images
Whether to stop disease-modifying therapy (DMT) in older patients with multiple sclerosis (MS) can be a fraught topic. Guidelines acknowledge that there are limited data to guide the decision and suggest that clinicians and patients can make this call together.
When it comes to treating patients with multiple sclerosis (MS), a new study shows that physicians and nurse practitioners (NPs) score similarly in regard to patient satisfaction.
The cost of treatment for multiple sclerosis (MS) has been the subject of GoFundMe campaigns, an investigation by members of Congress, and recent studies in Neurology and JAMA Neurology.
Infusible disease-modifying therapies for multiple sclerosis (MS) are disproportionately more effective at quelling disease activity than oral drugs in younger patients, an advantage that fades by about age 45 years, Enrique Alvarez, MD, PhD, reported at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Monitoring immunoglobulin levels regularly has become an imperative in patients with multiple sclerosis (MS) on anti-CD20 agents in light of consistent findings from long-term, open-label studies of rituximab and ocrelizumab presented at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Sheila DeMelle was diagnosed at age 17 with multiple sclerosis. For most of her life, her MS didn’t slow her down too much. “My disability was invisible. I knew I had it; I knew the symptoms,” but her symptoms weren’t readily apparent.
It’s taken almost 20 years, but the search for a widely usable, blood-based biomarker of multiple sclerosis (MS) disease activity is finally yielding results.
At first, Seattle-area resident Kellen Prouse blamed himself when sex became an ordeal after he was diagnosed with primary progressive multiple sclerosis. “I’m 27, and I’m saying, ‘What is wrong?’ It was hard to admit it was part of MS at first.”
Patient engagement in one’s disease management has long been hailed across specialties and chronic disease states as a key to better outcomes and care experiences. But what does it mean for multiple sclerosis specifically?